Szczepionka przeciw odrze

• Strebel P.M., Papania M.J., Fiebelkorn A.P. i in. Measles vaccines. w: Plotkin’s Vaccines, red. Plotkin S., Orenstein W., Offit P., Edwards M. wyd. 7, 2018, str. 579-18.
• Stanowisko WHO dot. szczepionki przeciwko odrze w języku angielskim i francuskim. Weekly Epidemiological Record „Measles vaccines: WHO position paper”, 2009, nr 35, str. 349-360.
• Centers for Disease Control. Measles, Mumps, and Rubella – Vaccine Use and Strategies for
  Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps:
  Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR z maja 1998/47(RR-8); str. 1-57.
• Program WHO eliminacji odry 2012-2020.
• Aktualne dane epidemiologiczne, gdzie podawana jest liczba zachorowań w poszczególnych krajach, uaktualniane  1/tydzień (Epidemiological update: Measles – monitoring European outbreaks, 22 June 2017)
• Anjali Jain, MD1; Jaclyn Marshall, MS1; Ami Buikema, MPH2; Tim Bancroft, PhD2; Jonathan P. Kelly, MPP1; Craig J. Newschaffer, PhD3. Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism  JAMA. 2015;313(15):1534-1540.
• Rowhani-Rahbar A. i wsp. Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children FREE. JAMA Pediatr. 2013;167(12):1111-1117.
• Arciuolo R.J. Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting- New York City. Clin. Infect Dis, 2017; 65, 1843-47.
• Stanowisko WHO „Measles vaccines: WHO position paper – April 2017”.
• Wendorf K.A. i wsp.  Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clin. Infect. Dis., 2017; 65: 226–232.

Reprezentatywne publikacje na temat skuteczności szczepień przeciw odrze:

• Ane B. Fisker, Eric Nebie, Anja Schoeps i wsp. A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine: Effects on Mortality and Measles Antibody Levels. Clinical Infectious Diseases. 2018; 66 (10): 1573-1580.
• Tom Woudenberg, Nicoline A. T. van der Maas, Mirjam J. Knol i wsp. Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6–14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study. The Journal of Infectious Diseases. 2017; 215 (8): 1181-1187.
• Jennifer L. Gardy, Monika Naus, Ashraf Amlani i wsp. Whole-Genome Sequencing of Measles Virus Genotypes H1 and D8 During Outbreaks of Infection Following the 2010 Olympic Winter Games Reveals Viral Transmission Routes. The Journal of Infectious Diseases 2015; 212 (10): 1574-1578.
• Amy Parker Fiebelkorn, Susan B. Redd, Paul A. Gastañaduy, i wsp. A Comparison of Postelimination Measles Epidemiology in the United States, 2009–2014 Versus 2001-2008. Journal of the Pediatric Infectious Diseases Society. 2017; 6 (1): 40-48.
• Wysocki J. Jak długo utrzymuje się ochrona po szczepieniu MMR? Medycyna Praktyczna Szczepienia. 28.05.2018.
• Franconeri L., Antona D., Cauchemez S. i wsp. Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017–2019. Vaccine, 2023 Aug 14: S0264-410X(23)00950-7.
• Sheppeard V. i wsp. The effectiveness of prophylaxis for measles contacts in NSW. NSW Public Health Bull. 2009;20(5-6):81–85.
• Barrabeig I. i wsp. Effectiveness of measles vaccination for control of exposed children. Pediatr Infect Dis J. 2011;30(1):78–80.